

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

<b>Effective Date:</b>	<b>9/1/2023</b>
------------------------	-----------------

[POLICY RATIONALE](#)  
[DISCLAIMER](#)  
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)  
[DEFINITIONS](#)  
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)  
[BENEFIT VARIATIONS](#)  
[REFERENCES](#)

### I. POLICY

Genetic testing for Factor V Leiden (FVL) and Factor II c.\*97G>A (G20210A) may be considered **medically necessary** for any one (1) of the following indications:

- A first unprovoked venous thromboembolism (VTE), especially less than 50 years old; **or**
- VTE at unusual sites (such as hepatic portal, mesenteric, and cerebral veins); **or**
- Recurrent VTE; **or**
- Personal history of VTE with:
  - two or more family members with a history of VTE; **or**
  - one first-degree relative with VTE at a young age; **or**
- Members with low activated protein C (APC) resistance activity; **or**
- Females under the age of fifty who smoke tobacco and have a history of acute myocardial infarction; **or**
- Siblings of individuals known to be homozygous for Factor V (Leiden) or Factor II (c.\*97G>A) (they have a 1 in 4 chance of being a homozygote); **or**
- Women of reproductive age who have:
  - A first-degree relative with unprovoked VTE or VTE provoked by pregnancy or contraceptive use; **or**
  - A first-degree relative with a history of VTE who is a known carrier for factor V Leiden and/or factor II c.97\*G>A variant; **or**
  - Personal history of VTE associated with a transient risk factor (pregnancy, estrogen-progestin contraceptive use, femoral fracture, surgery, or prolonged immobilization).
  - A positive or negative result of the genetic test will impact the clinical management (predictive, diagnostic, prognostic or therapeutic) of the individual.

Testing for protein C deficiency, protein S deficiency and antithrombin III deficiency may be considered **medically necessary** in members without recurrent VTE risk factors (for example, surgery, prolonged immobilization, collagen vascular disease, malignancy, certain hematologic disorders) in any of the following situations:

- A venous thromboembolism (VTE) before the age of fifty; **or**
- VTE at unusual sites (such as hepatic, mesenteric, and cerebral veins); **or**
- VTE and a strong family history of thrombotic disease; **or**
- Relatives of members with VTE before age 50; **or**
- Females under the age of fifty who smoke tobacco and have a history of acute myocardial infarction; **or**

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

- Women who wish to start oral contraceptives with personal or family history of VTE; **or**
- VTE during pregnancy or women taking oral contraceptives; **or**
- Members with warfarin-induced skin necrosis; **or**
- Infants who develop Neonatal Purpura Fulminans; **or**
- Pediatric arterial ischemic stroke

Note: Testing should be performed at least six weeks after acute thrombotic event and while the individual is not taking anticoagulants.

Routine testing for members with a personal or family history of arterial thrombotic disorders (such as coronary artery disease or ischemic stroke) is considered **not medically necessary**, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure

MTHFR (5,10-methylenetetrahydrofolate reductase enzyme) polymorphism testing is considered **investigational**, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure. **(See Policy Guideline)**

All other indications of genetic testing for inherited thrombophilia other than those described in the policy section are considered **investigational**, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

### **POLICY GUIDELINES**

#### **Genetic Counseling**

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

#### **American College of Medical Genetics and Genomics (ACMG)**

American College of Medical Genetics and Genomics (ACMG) is a nationally recognized interdisciplinary professional organization that is composed of a medical genetics team including clinical geneticists, clinical laboratory geneticists, and genetic counselors. In 2018, ACMG technical standards were updated on Venous thromboembolism laboratory testing (Factor V Leiden and Factor II c.\*97G>A).

Testing for factor V Leiden and factor II c.\*97G>A is recommended in the following circumstances:

- A first unprovoked VTE, especially <50 years old.
- VTE at unusual sites (such as hepatic portal, mesenteric, and cerebral veins).
- Recurrent VTE.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

- Personal history of VTE with (a) two or more family members with a history of VTE or (b) one first-degree relative with VTE at a young age.
- Patients with low activated protein C (APC) resistance activity.

Testing may be considered in the following circumstances:

- Females under the age of fifty who smoke tobacco and have a history of acute myocardial infarction.
- Siblings of individuals known to be homozygous for factor V Leiden or factor II c.\*97G>A because they have a 1 in 4 chance of being a homozygote.
- Asymptomatic pregnant female or female contemplating pregnancy, with a first-degree relative with unprovoked VTE or VTE provoked by pregnancy or contraceptive use.
- Pregnant female or female contemplating pregnancy or estrogen use who has a first-degree relative with a history of VTE and is a known carrier for factor V Leiden and/or factor II c.97\*G>A variant.
- Pregnant female or female contemplating pregnancy with a previous non-estrogen-related VTE or VTE provoked by a minor risk factor because knowledge of the factor V Leiden or factor II c.\*97G>A status may alter pregnancy-related thrombophylaxis.

Per the American Society of Hematology, thrombophilia testing in patients with transient risk factors (such as surgery, immobility, or trauma) has the potential to cause harm if the duration of anticoagulation is inappropriately prolonged.

### **MTHFR polymorphism testing**

MTHFR (5,10-methylenetetrahydrofolate reductase enzyme) polymorphism testing has been shown to have minimal utility in the routine evaluation of thrombophilia.

Per the Society for Maternal-Fetal Medicine, women should not be tested for MTHFR mutations. Due to the lack of evidence associating genotype independently with thrombosis, recurrent pregnancy loss, or other adverse pregnancy outcomes, MTHFR genotyping should not be ordered as part of a workup for thrombophilia.

In 2021, American Society for Clinical Laboratory Science (ASCLS) published guidelines on Choosing Wisely to suggest against ordering a homocysteine assay as part of the thrombophilia work up. “An elevated homocysteine level is not a clotting disorder and should not be included in thrombophilia testing panels”

### **Genetics Nomenclature Update**

Human Genome Variation Society (HGVS) nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). HGVS nomenclature is recommended by HGVS, the Human Variome Project, and the HUman Genome Organization (HUGO).

The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) standards and guidelines for interpretation of sequence variants

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

represent expert opinion from ACMG, AMP, and the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
<b>Mutation</b>	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

Variant Classification	Definition
<b>Pathogenic</b>	Disease-causing change in the DNA sequence
<b>Likely pathogenic</b>	Likely disease-causing change in the DNA sequence
<b>Variant of uncertain significance</b>	Change in DNA sequence with uncertain effects on disease
<b>Likely benign</b>	Likely benign change in the DNA sequence
<b>Benign</b>	Benign change in the DNA sequence

American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

**II. PRODUCT VARIATIONS**

[Top](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

**III. DESCRIPTION/BACKGROUND**

[Top](#)

Inherited thrombophilias are a group of disorders that predispose to thrombosis. Genetic testing is available for some of these disorders and could potentially assist in the diagnosis and/or management of patients with thrombosis. For example, testing is available for types of inherited thrombophilia, including variants in the 5,10-methylenetetrahydrofolate reductase (*MTHFR*) gene, the factor V gene (factor V Leiden [FVL] variant), and the prothrombin (factor II) gene. Plasma testing is also available for protein C, protein S and antithrombin III deficiencies.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

### Venous Thromboembolism

The overall U.S. incidence of venous thromboembolism (VTE) is approximately 1 per 1,000 person-years, and the lifetime clinical prevalence is about 5%, accounting for 100,000 deaths annually. Risk is strongly age-related, with the greatest risk in older populations. VTE also recurs frequently; the estimated cumulative incidence of first VTE recurrence is 30% at 10 years. These figures do not separate patients who had known predisposing conditions from those without.

Risk factors for thrombosis include a variety of clinical and demographic variables, and at least one risk factor can be identified in approximately 80% of patients with a thrombosis. The following list includes the most important risk factors:

- Malignancy
- Immobility
- Surgery
- Obesity
- Pregnancy
- Hormonal therapy with estrogen/progesterone
- Systemic lupus erythematosus (SLE), and/or other rheumatologic disorders
- Myeloproliferative disorders
- Liver dysfunction
- Nephrotic syndrome
- Hereditary factors

Pregnancy often is considered a special circumstance because of its frequency and unique considerations of preventing and treating VTE. Pregnancy is associated with a 5- to 10-fold increase in VTE risk, and absolute VTE risk in pregnancy is estimated to be 1 to 2 per 1000 deliveries. In women with a history of pregnancy-related VTE, risk of recurrent VTE with subsequent pregnancies is increased greatly at approximately 100-fold.

### Treatment

Treatment of thrombosis involves anticoagulation for a minimum of 3 to 6 months. Following this initial treatment period, patients deemed to be at a continued high risk for recurrent thrombosis may be continued on anticoagulation for longer periods, sometimes indefinitely. Anticoagulation is effective in reducing the subsequent risk of thrombosis but has its own risks of bleeding.

### Inherited Thrombophilia

Inherited thrombophilias are a group of clinical conditions in which there is a genetic variant defect associated with a predisposition to thrombosis. Not all patients with a genetic predisposition to thrombosis will develop VTE. The presence of inherited thrombophilia will presumably interact with other VTE risk factors to determine an individual's risk of VTE.

A number of conditions fall under the classification of inherited thrombophilias. Inherited thrombophilias include the following conditions, which are defined by defects in the coagulation cascade:

- Activated protein C resistance (factor V Leiden [FVL] variant)
- Prothrombin (factor II) gene variant (G20210A)

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

- Protein C deficiency
- Protein S deficiency
- Prothrombin deficiency
- Hyper-homocysteinemia (5,10-methylenetetrahydrofolate reductase [MTHFR] variant)

The most common type of inherited thrombophilia is a factor V Leiden variant, which accounts for up to 50% of the inherited thrombophilia syndromes. In unselected patients with an idiopathic thrombosis, the rate of factor V Leiden positivity is in the range of 17-24%, compared to a rate of 5-6% in normal controls. The prothrombin gene variant is found less commonly, in approximately 5-8% of unselected patients with thrombosis, compared to 2-2.5% of normal controls.

The second most common inherited thrombophilia is the G20210A mutation of prothrombin. This mutation is a gain of function mutation where clotting activity is increased by creating more thrombin and fibrin. The overall prevalence of this mutation is about 2%. Genetic defects of antithrombin (an inhibitor of thrombin) may also occur, but the estimated prevalence of antithrombin defects is only a maximum of 0.2%.

Protein C deficiency is a genetic disorder characterized by a deficiency of protein C, which is a natural anticoagulant. Although very rare, there is a severe form that is present at birth (congenital) and can potentially cause widespread small clots in the body and life-threatening complications in infancy. Protein C deficiency is caused by alterations (mutations) in the *PROC* gene. The common form is caused by an alteration in one *PROC* gene. The severe form is caused by an alteration in both *PROC* genes.

Antithrombin deficiency is a blood disorder characterized by the tendency to form venous thrombosis. Antithrombin limits the blood's ability to clot (coagulation) and the primary inhibitor of thrombin, which is required for the development of blood clots. In people with congenital antithrombin deficiency, there is a reduced amount of this substance in the blood due to a genetic abnormality.

Protein S deficiency is a rare inherited disorder characterized by the formation of recurrent blood clots and emboli. Affected individuals are particularly at risk for developing deep vein thrombosis. In severe cases of protein S deficiency, infants may develop a potentially life-threatening complication called purpura fulminans. Protein S deficiency is caused by alterations in the *PROS1* gene.

### Genetic Testing

Genetic testing for gene variants associated with thrombophilias is available for factor V Leiden, the prothrombin gene variant, and the *MTHFR* gene. The use of genetic testing for inherited thrombophilia can be considered in several clinical situations. The clinical situations that will be addressed in this policy include the following:

- Assessment of the risk for thrombosis in asymptomatic patients (screening for inherited thrombophilia)
- Evaluation of a patient with established thrombosis, in consideration of change in anticoagulant management based on results

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

- Evaluation of close relatives of patients with documented inherited thrombophilia, or with a clinical and family history that is consistent with an inherited thrombophilia
- Evaluation of patients in other situations that are considered high risk for thrombosis (e.g., pregnancy, planned major surgery, or oral contraceptive use).

### Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Commercial thrombophilia genetic tests are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

Several genetic tests for thrombophilia have been cleared for marketing by FDA through the 510(k) process for use as an aid in the diagnosis of patients with suspected thrombophilia. Some of these tests are listed in Table 1.

**Table 1. Genetic Tests for Thrombophilia Cleared by FDA**

Test	Manufacturer	Location	Date Cleared	510(k) No.
IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test	Agena Bioscience <sup>a</sup>	San Diego, CA	06/14	K132978
Invader® Factor II, V, and MTHFR (677, 1298) tests	Hologic	Marlborough, MA	04-06/11	K100943, K100980, K100987, K100496
VeraCode® Genotyping Test for Factor V and Factor II	Illumina	San Diego, CA	04/28/10	K093129
eSensor® Thrombophilia Risk Test, FII-FV, FII, FV and MTHFR (677, 1298) Genotyping Tests	GenMark Dx <sup>b</sup>	Carlsbad, CA	04/22/10	K093974
INFINITI™ System Assay for Factor II & Factor V	AutoGenomics	Carlsbad, CA	02/07/07	K060564
Xpert® Factor II and Factor V Genotyping Assay	Cepheid	Sunnyvale, CA	09/18/09	K082118
Verigene® Factor F2, F5, and MTHFR Nucleic Acid Test	Nanosphere	Northbrook, IL	10/11/07	K070597
Factor V Leiden Kit	Roche Diagnostics	Indianapolis, IN	12/17/03	K033607
Factor II (Prothrombin) G20210A Kit	Roche Diagnostics	Indianapolis, IN	12/20/03	K033612

FDA: Food and Drug Administration.

<sup>a</sup> FDA marketing clearance was granted to Sequenom Bioscience before it was acquired by Agena Bioscience.

<sup>b</sup> FDA marketing clearance was granted to Osmetech Molecular Diagnostics.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

Other commercial laboratories may offer a variety of functional assays and genotyping tests for F2 (prothrombin, coagulation factor II) and F5 (coagulation factor V), and single or combined genotyping tests for MTHFR.

Commercial laboratories may offer a variety of functional assays and genotyping tests for protein C, protein S and antithrombin III.

On April 6, 2017, FDA permitted marketing of 23andMe Personal Genome Service Genetic Health Risk tests for ten diseases or conditions. These direct-to-consumer tests are the first authorized by FDA that provide information on an individual’s genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional. The 23andMe Genetic Health Risk tests work by isolating DNA from a saliva sample, which is then tested for more than 500,000 genetic variants. The presence or absence of some of these variants is associated with an increased risk of developing any 1 of 10 diseases or conditions. Testing for hereditary thrombophilia (2 variants in the F5 and F2 genes; relevant for European descent) is included.

**IV. RATIONALE**

[TOP](#)

**Summary of Evidence**

For individuals who are asymptomatic with or without a personal or family history of VTE or who are asymptomatic with increased VTE risk (e.g., due to pregnancy) who receive genetic testing for variants in *MTHFR*, or genetic testing for coagulation factor V and coagulation factor II, the evidence includes a large randomized controlled trial, prospective cohort analyses, retrospective family studies, case-control studies, and meta-analyses. Relevant outcomes are morbid events and treatment-related morbidity. The clinical validity of genetic testing has been demonstrated by the presence of a factor V Leiden variant or a prothrombin gene variant, and an association with an increased risk for subsequent VTE across various populations studied. However, the magnitude of the association is relatively modest, with odds ratios most commonly between 1 and 2, except for family members of individuals with inherited thrombophilia, for whom odds ratios are somewhat higher. The clinical utility of testing for factor V Leiden or prothrombin variants has not been demonstrated. Although the presence of inherited thrombophilia increases the risk for subsequent VTE events, the increase is modest, and the absolute risk of thrombosis remains low. Available prophylactic treatments (e.g., anticoagulation) have defined risks of major bleeding and other adverse events that may outweigh the reduction in VTE and therefore result in net harm. Currently, available evidence has not defined a role for thrombophilia testing for decisions on initiation of prophylactic anticoagulation or the length of anticoagulation treatment. For *MTHFR* testing, clinical validity and clinical utility of genetic testing are uncertain. Because clinical utility of testing for elevated serum homocysteine itself has not been established, the utility of genetic testing also has not been established. The evidence is insufficient to determine the effects of the technology on health outcomes.

*MTHFR* [5,10-methylenetetrahydrofolate reductase enzyme] polymorphism testing is frequently ordered by physicians as part of the clinical evaluation for thrombophilia. It was previously hypothesized that reduced enzyme activity of *MTHFR* led to mild hyperhomocysteinemia which led to an increased risk for venous thromboembolism, coronary heart disease, and recurrent pregnancy loss. Recent meta-analyses have disproven an association between



## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

hyperhomocysteinemia and risk for coronary heart disease and between MTHFR polymorphism status and risk for venous thromboembolism. There is growing evidence that MTHFR polymorphism testing has minimal clinical utility and therefore should not be ordered as a part of a routine evaluation for thrombophilia.

### V. DEFINITIONS

[TOP](#)

N/A

### VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

### VII. DISCLAIMER

[TOP](#)

*Capital Blue Cross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.*

### VIII. CODING INFORMATION

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Investigational; therefore, not covered:**

Procedure Codes								
81291								

**Covered when medically necessary:**

Procedure Codes								
81240	81241	85300	85301	85302	85303	85305	85306	85307

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

<b>ICD-10-CM Diagnosis Code*</b>	<b>Description</b>
D68.51	Activated protein C resistance
D68.52	Prothrombin gene mutation
D68.59	Other primary thrombophilia
D68.62	Lupus anticoagulant syndrome
D68.61	Antiphospholipid syndrome
D68.69	Other thrombophilia

### IX. REFERENCES

[TOP](#)

1. American Board of Internal Medicine Foundation. *Choosing Wisely*. July 2021
2. American College of Obstetricians Gynecologists, Women's Health Care Physicians. *ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy*. *Obstet Gynecol*. Sep 2013;122(3):706-717. PMID 23963422
3. Baglin T, Gray E, Greaves M, et al. *Clinical guidelines for testing for heritable thrombophilia*. *Br J Haematol*. Apr 2010;149(2):209-220. PMID 20128794
4. Bezemer ID, Doggen CJ, Vos HL, et al. *No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study*. *Arch Intern Med*. Mar 12, 2007;167(5):497-501. PMID 17353498
5. Bradley LA, Palomaki GE, Bienstock J, et al. *Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes? Results from a targeted evidence-based review*. *Genet Med*. Jan 2012;14(1):39-50. PMID 22237430
6. Chatterjee T, Gupta N, Choudhry VP, et al. *Prediction of ischemic stroke in young Indians: is thrombophilia profiling a way out? Blood Coagul Fibrinolysis*. Jun 2013;24(4):449-453. PMID 23337710
7. Christiansen SC, Cannegieter SC, Koster T, et al. *Thrombophilia, clinical factors, and recurrent venous thrombotic events*. *JAMA*. May 18, 2005;293(19):2352-2361. PMID 15900005
8. Clark P, Walker ID, Langhorne P, et al. *SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage*. *Blood*. May 27, 2010;115(21):4162-4167. PMID 20237316
9. Coppens M, Reijnders JH, Middeldorp S, et al. *Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis*. *J Thromb Haemost*. Sep 2008;6(9):1474-1477. PMID 18540999
10. de Jong PG, Kaandorp S, Di Nisio M, et al. *Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia*. *Cochrane Database Syst Rev*. Jul 04 2014(7):CD004734. PMID 24995856
11. den Heijer M, Willems HP, Blom HJ, et al. *Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized,*

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

placebo-controlled, double-blind trial. *Blood*. Jan 1, 2007;109(1):139-144. PMID 16960155

12. EGAPP Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. *Genet Med*. Jan 2011;13(1):67-76. PMID 21150787
13. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. *Thromb Haemost*. Aug 2009;102(2):360-370. PMID 19652888
14. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. Feb 2012;141(2 Suppl):7S-47S. PMID 22315257
15. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. *Thromb Haemost*. Jul 2001;86(1):452-463. PMID 11487036
16. Hickey, S. E., Curry, C. J., & Toriello, H. V. (2013). ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. *Genetics in medicine : official journal of the American College of Medical Genetics*, 15(2), 153–156.
17. Hindorff LA, Burke W, Laberge AM, et al. Motivating factors for physician ordering of factor V Leiden genetic tests. *Arch Intern Med*. Jan 12, 2009;169(1):68-74. PMID 19139326
18. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. Jun 2008;133(6 Suppl):110S-112S. PMID 18574260
19. Joachim E, Goldenberg NA, Bernard TJ, et al. The methylenetetrahydrofolate reductase polymorphism (MTHFR c.677C>T) and elevated plasma homocysteine levels in a U.S. pediatric population with incident thromboembolism. *Thromb Res*. Aug 2013;132(2):170-174. PMID 23866722
20. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. *N Engl J Med*. Apr 29, 2010;362(17):1586-1596. PMID 20335572
21. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest*. Feb 2016;149(2):315-352. PMID 26867832
22. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. *Blood*. Dec 1, 2008;112(12):4432-4436. PMID 18791166
23. Kujovich JL. Prothrombin-Related Thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2014.
24. Li P, Qin C. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and susceptibility to ischemic stroke: a meta-analysis. *Gene*. Feb 10, 2014;535(2):359-364. PMID 24140489
25. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. *Blood*. May 21, 2009;113(21):5314-5322. PMID 19139080

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

26. Lockwood, C. & Bauer, K. *Inherited thrombophilias in pregnancy*. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; updated 03/31/2020
27. Mahajerin A, Obasaju P, Eckert G, et al. *Thrombophilia testing in children: a 7-year experience*. *Pediatr Blood Cancer*. Mar 2014;61(3):523-527. PMID 24249220
28. Middeldorp S, Henkens CM, Koopman MM, et al. *The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis*. *Ann Intern Med*. Jan 1, 1998;128(1):15-20. PMID 9424976
29. Press RD, Bauer KA, Kujovich JL, et al. *Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders*. *Arch Pathol Lab Med*. Nov 2002;126(11):1304-1318. PMID 12421138
30. Pruller F, Weiss EC, Raggam RB, et al. *Activated protein C resistance assay and factor V Leiden*. *N Engl J Med*. Aug 14, 2014;371(7):685-686. PMID 25119624
31. Rodger MA, Hague WM, Kingdom J, et al. *Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial*. *Lancet*. Nov 08, 2014;384(9955):1673-1683. PMID 25066248
32. Russo PD, Damante G, Pasca S, et al. *Thrombophilic mutations as risk factor for retinal vein occlusion: a case-control study*. *Clin Appl Thromb Hemost*. May 2015;21(4):373-377. PMID 24569626
33. Segal JB, Brotman DJ, Emadi A, et al. *Outcomes of genetic testing in adults with a history of venous thromboembolism (Evidence Reports/Technology Assessment, No. 180)*. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
34. Silver RM, Saade GR, Thorsten V, et al. *Factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network*. *Am J Obstet Gynecol*. Oct 2016;215(4):468 e461-468 e417. PMID 27131585
35. Skeith L, Carrier M, Kaaja R, et al. *A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia*. *Blood*. Mar 31, 2016;127(13):1650-1655. PMID 26837697
36. Supanc V, Sonicki Z, Vukasovic I, et al. *The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals*. *J Stroke Cerebrovasc Dis*. Mar 2014;23(3):e171-176. PMID 24189452
37. Vandenbroucke JP, Koster T, Briet E, et al. *Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation*. *Lancet*. Nov 26, 1994;344(8935):1453-1457. PMID 7968118
38. Zhang, S., Taylor, A.K., Huang, X. et al. *Venous thromboembolism laboratory testing (factor V Leiden and factor II c.\*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG)*. *Genet Med* 20, 1489–1498 (2018)., Qian W, Li J, et al. *Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis*. *Thromb Res*. Nov 2013;132(5):531-536. PMID 24074702
39. Society for Maternal-Fetal Medicine Publications Committee. *American Board of Internal Medicine (ABIM) Foundation Choosing Wisely Campaign*. December 2022.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

40. Ashraf N, Visweshwar N, Jaglal M, Sokol L, Laber D. Evolving paradigm in thrombophilia screening. *Blood Coagul Fibrinolysis*. 2019;30(5):249-252. doi:10.1097/MBC.0000000000000809

41. American Society for Clinical Laboratory Science. American Board of Internal Medicine (ABIM) Foundation Choosing Wisely Campaign. September 2021

42. Bauer, K. Protein C Deficiency. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated 11/16/2021

43. Bauer, K. Prothrombin G20210A mutation. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated 12/20/2021

44. Bauer, K. Screening for Inherited Thrombophilia in Asymptomatic Adults. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; Feb 2023. Last updated: Aug 16, 2021

45. Bauer, K. Evaluating Adult Patients with Established Venous Thromboembolism for Acquired and Inherited Risk Factors. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; Literature review current through: Feb 2023. Last updated: Oct 25, 2022

46. National Organization for Rare Disorders. Antithrombin Deficiency. 2018

47. National Organization for Rare Disorders. Protein S Deficiency. 2019

48. National Organization for Rare Disorders. Protein C Deficiency. 2018

49. National Institute for Health Care Excellence Guidelines. Venous Thromboembolic Disease: Diagnosis, Management, and Thrombophilia Testing. March 26, 2020

50. American College of Obstetricians Gynecologists. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding. Committee Opinion, Number 785, September 2019.

51. Case Report: Managing Menorrhagia in a Familial Case of Factor V Deficiency. Department of Obstetrics and Gynecology, University of Medicine-Jacksonville, Jacksonville, FL. *Journal of Pediatric Adolescent Gynecology* 28(2015) e9-e12.

52. Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.04.82, Genetic Testing for Inherited Thrombophilia. June 2022

**X. POLICY HISTORY**

[Top](#)

<b>MP 2.253</b>	<b>CAC 7/30/13 New policy.</b> BCBSA adopted. Genetic testing for inherited thrombophilia is considered investigational.
	<b>6/18/14 Admin change.</b> Medicare variation added to reference LCD L33640 Biomarkers Overview. Added FEP variation to reference MP-2.04.82 Genetic Testing for Inherited Thrombophilia in the manual.
	<b>CAC 5/20/14 Consensus review.</b> FEP variation added to refer to the FEP manual. No change to the policy statements. Codes reviewed.
	<b>CAC 6/2/15 Consensus review.</b> No change to the policy statement. Rationale and references updated. No coding changes.
	<b>CAC 11/24/15 Minor review.</b> Updated medical literature. No change to policy statements. References and rationale updated. LCD revised from LCD L33638 to L35062 due to Novitas ICD-10 LCD update. Coding reviewed.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR INHERITED THROMBOPHILIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.253</b>

	<b>CAC 11/29/16 Consensus review.</b> Policy statement unchanged. Variation reformatting completed. Description/Background, Rationale and Reference sections updated. Appendix added. Coding reviewed.
	<b>CAC 12/19/17 Consensus review.</b> No change to policy statements. References and rationale updated.
	<b>10/24/18</b> Code review completed. No changes.
	<b>1/17/19 Consensus review.</b> No change to policy statements. References and rationale updated.
	<b>1/24/2020 Minor review.</b> Adding medically necessary indications per American College of Medical Genetics. References updated. Coding reviewed.
	<b>8/19/2020 Minor review.</b> Medically necessary indications for Factor II and Factor V expanded to address additional indications. .Investigational statement for routine testing and MTHFR clarified. Policy guideline, product variation, description/background, rationale, benefit variation, disclaimer, and references updated. Coding reviewed.
	<b>8/27/2021</b> Spelling correction for necessary.
	<b>11/2/2021 Consensus.</b> References updated; coding reviewed
	<b>08/09/2022 Minor Review.</b> Adding MN testing for protein c, protein s and antithrombin III deficiencies. Added codes 85300, 85301, 85302, 85303, 85305, 85306, 85307. Guidelines, background, references, and formatting updated.
	<b>3/23/2023 Consensus review.</b> No change to policy statements. References updated. No coding changes.
	<b>7/26/2023 Ad Hoc minor review.</b> Medically necessary indications expanded to include women of reproductive age who have a positive or negative result of the genetic test will impact the clinical management. References updated.

[Top](#)

*Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*